Epiphany Biosciences, Inc. Announces Appointments to Its Board of Directors
SAN FRANCISCO, March 30 /PRNewswire/ -- Epiphany Biosciences, Inc. announced six appointments to its board of directors. The directors include Charles Sanders, MD, former Chairman and CEO of Glaxo, Inc.; Clyde T. Turner, Chairman and CEO of Global Trust Ventures, LLC; John Quelch, DBA, MBA, MS, Senior Associate Dean and Lincoln Filene Professor of Business Administration at Harvard Business School; Paul A. Mieyal, PhD, CFA, Vice President of Wexford Capital LLC; Lee Meisel, MD, MPH, JD, President of Windsor Bay Capital; and Fred Volinsky, MD, Epiphany's CEO, who will also serve as Chairman of the board. A seventh board seat remains to be filled.
"We are thrilled to have assembled a board with such superlative technical, financial, and operational experience," said Epiphany CEO Fred Volinsky. "The board's depth and breadth of knowledge are tremendous assets that will help Epiphany achieve its mission of bringing life improving therapies to patients with acute and chronic disease."
Charles Sanders, MD served as Chief Executive Officer of Glaxo Inc., a pharmaceutical company, from 1989 to 1994, and was the Chairman of the Board of Glaxo Inc. from 1992 to 1995. Dr. Sanders is also on the Boards of Directors of Vertex Pharmaceuticals, Biopure Corporation, Cephalon, Inc., Fisher Scientific International, Icagen, Inc., and Genentech where he is presently the lead director.
Clyde T. Turner is Chairman and Chief Executive Officer of Global Trust Ventures, LLC, a private equity fund he co-founded in 2005 and Chairman and Chief Executive Officer of Turner Investment, Ltd., a general purpose investment company he founded in 1998. He has served as President and Chief Financial Officer then Chairman and Chief Executive Officer of Mandalay Bay Group and has served as Executive Vice President and Chief Financial Officer of Mirage Resorts, Inc. Mr. Turner serves on the Community Board of Directors of St. Rose Hospitals in Las Vegas, Nevada, and sits on its Quality Control Committee. He serves as a member of the Board of Directors of Sierra Pacific Resources . From 1995 through 2005 Mr. Turner served on the Board of Directors CaPCURE, an organization founded to find a cure for prostate cancer.
John A. Quelch, DBA, MBA, MS is Senior Associate Dean and Lincoln Filene Professor of Business Administration at Harvard Business School. Between 1998 and 2001 he was Dean of London Business School. Prior to 1998, he was the Sebastian S. Kresge Professor of Marketing and Co-Chair of the Marketing Area at Harvard Business School. Professor Quelch's research focus is on global marketing and branding in emerging as well as developed markets. Professor Quelch is a non-executive director of WPP Group plc, Pepsi Bottling Group, Gentiva Health Services and Inverness Medical Innovations Inc. He also serves pro bono as Chairman of the Port Authority of Massachusetts and as Honorary Consul General of Morocco in New England.
Paul A. Mieyal, Ph.D., CFA is a Vice President of Wexford Capital LLC, an SEC registered investment advisor with over $5 billion of assets under management located in Greenwich, CT. Prior to that, he was Vice President in charge of healthcare investments for Wechsler & Co., Inc., a private investment firm and registered broker-dealer. Dr. Mieyal serves as a Director of Tigris Pharmaceuticals, Inc., Danube Pharmaceuticals, Inc., and Microbiogen Pty Ltd. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.
Lee Meisel, MD, MPH, JD is president of Windsor Bay Capital, Inc. and managing member of Orion Capital Group, LLC. He currently serves as a director of Targa Therapeutics Corporation. Dr. Meisel previously was Vice President, Operations and director of CPS Chemical Corporation. While at CPS Chemical, Dr. Meisel was a member of the executive management team that sold the company to Allied Colloids in the United Kingdom. He received his law degree from Stanford Law School and completed his medical training as a fellow in critical care medicine and a resident in anesthesiology at Harvard Medical School. His Masters of Public Health degree is from the Harvard School of Public Health. About Epiphany Biosciences
Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany's team includes a world-class group of virologists, clinical development, and drug discovery experts. The founders include Fred Volinsky MD, Robert Gallo MD, David Myles PhD, Barry Selick PhD and Lee Meisel MD, MPH, JD. Epiphany is located in San Francisco, California.
Additional information on Epiphany Biosciences may be obtained at the company website http://www.epiphanybio.com or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193; David C. Myles PhD, COO 415.765.7198.
Epiphany Biosciences Inc.CONTACT: Fred G. Volinsky, MD, CEO, +1-415-765-7193, or David C. MylesPhD, COO, +1-415-765-7198, both of Epiphany Biosciences Inc.
Web site: http://www.epiphanybio.com//